Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COR 
Cencora Inc. (COR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: COR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $332.07
1 Year Target Price $332.07
| 10 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 37.37% | Avg. Invested days 68 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 56.06B USD | Price to earnings Ratio 29.69 | 1Y Target Price 332.07 |
Price to earnings Ratio 29.69 | 1Y Target Price 332.07 | ||
Volume (30-day avg) 17 | Beta 0.58 | 52 Weeks Range 217.25 - 308.75 | Updated Date 08/13/2025 |
52 Weeks Range 217.25 - 308.75 | Updated Date 08/13/2025 | ||
Dividends yield (FY) 0.74% | Basic EPS (TTM) 9.74 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-08-06 | When Before Market | Estimate 3.84 | Actual 4 |
Profitability
Profit Margin 0.6% | Operating Margin (TTM) 1.22% |
Management Effectiveness
Return on Assets (TTM) 3.1% | Return on Equity (TTM) 116.71% |
Valuation
Trailing PE 29.69 | Forward PE 16.61 | Enterprise Value 62068423291 | Price to Sales(TTM) 0.18 |
Enterprise Value 62068423291 | Price to Sales(TTM) 0.18 | ||
Enterprise Value to Revenue 0.2 | Enterprise Value to EBITDA 15.44 | Shares Outstanding 193878000 | Shares Floating 183466639 |
Shares Outstanding 193878000 | Shares Floating 183466639 | ||
Percent Insiders 5.3 | Percent Institutions 94.42 |
Upturn AI SWOT
Cencora Inc.
Company Overview
History and Background
Cencora, Inc., formerly AmerisourceBergen Corporation, was founded in 2001 through the merger of Bergen Brunswig and AmeriSource Health Corporation. The company has grown through acquisitions and organic expansion to become a leading pharmaceutical distributor.
Core Business Areas
- Pharmaceutical Distribution: Distributes branded and generic pharmaceuticals, specialty pharmaceuticals, and over-the-counter healthcare products to pharmacies, hospitals, and healthcare providers.
- Specialty Distribution and Services: Provides services for specialty pharmaceuticals, including distribution, clinical support, and reimbursement assistance.
- Healthcare Solutions: Offers a range of solutions including data analytics, consulting, and technology services to healthcare providers and manufacturers.
Leadership and Structure
Steven H. Collis is the Chairman, President and Chief Executive Officer. The company has a board of directors and operates through various business segments, with executive leadership overseeing each area.
Top Products and Market Share
Key Offerings
- Branded Pharmaceuticals: Distribution of branded drugs represents a significant portion of Cencora's revenue. The exact market share for specific drugs varies, but Cencora is a leading distributor alongside Cardinal Health and McKesson. Competitors include Cardinal Health (CAH) and McKesson (MCK).
- Generic Pharmaceuticals: Distribution of generic drugs is another key offering. Similar to branded drugs, Cencora's market share is substantial, competing with Cardinal Health and McKesson. Competitors include Cardinal Health (CAH) and McKesson (MCK).
- Specialty Pharmaceuticals: Focus on distributing specialty drugs for complex diseases. They work with pharmaceutical manufacturers to offer support and deliver innovative therapies to care providers. Market share is significant but specifics are hard to obtain.
Market Dynamics
Industry Overview
The pharmaceutical distribution industry is characterized by high regulation, consolidation, and intense competition. It serves as a critical link between pharmaceutical manufacturers and healthcare providers.
Positioning
Cencora is a leading player in the industry, known for its scale, distribution network, and specialized services. Competitive advantages include established relationships with manufacturers and providers, as well as their expanding services portfolio.
Total Addressable Market (TAM)
The global pharmaceutical distribution market is estimated to be in the hundreds of billions of dollars annually. Cencora is positioned to capture a significant portion of this TAM through its core distribution business and expanding service offerings.
Upturn SWOT Analysis
Strengths
- Large scale and efficient distribution network
- Strong relationships with manufacturers and providers
- Diversified portfolio of products and services
- Leading position in specialty pharmaceuticals
Weaknesses
- High dependence on a few key customers
- Exposure to pricing pressures and regulatory changes
- Debt levels from acquisitions
- Profit margins relatively low compared to other industries
Opportunities
- Expanding into new markets and geographies
- Increasing demand for specialty pharmaceuticals
- Growing need for healthcare solutions and services
- Further consolidation in the distribution industry
Threats
- Increased competition from other distributors
- Government regulations and pricing controls
- Changes in pharmaceutical manufacturing landscape
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- MCK
- CAH
Competitive Landscape
Cencora competes with McKesson and Cardinal Health for market share. Each company has its own strengths and weaknesses, with Cencora focusing on specialty pharmaceuticals and value-added services.
Major Acquisitions
PharMEDium Healthcare Corporation
- Year: 2015
- Acquisition Price (USD millions): 2575
- Strategic Rationale: Expanded Cencora's presence in the compounded sterile preparations market.
World Courier
- Year: 2012
- Acquisition Price (USD millions): 520
- Strategic Rationale: Expanded Cencorau2019s reach globally and built leadership in specialty logistics.
Growth Trajectory and Initiatives
Historical Growth: Cencora has grown both organically and through acquisitions, with revenue growth driven by increased demand for pharmaceuticals and healthcare services.
Future Projections: Analyst estimates suggest continued growth for Cencora, driven by favorable industry trends and strategic initiatives. Revenue is expected to grow in the mid-single digits.
Recent Initiatives: Recent initiatives include expanding specialty pharmaceutical services, investing in technology, and pursuing strategic acquisitions.
Summary
Cencora is a strong player in pharmaceutical distribution, leveraging a large network and strategic acquisitions to maintain its position. The company is strategically positioned to benefit from expanding health needs. However, it faces pricing pressures and regulatory scrutiny. Cencora needs to continue to look to diversify to improve margins. Overall, Cencora's strong market position and strategic initiatives suggest a positive outlook.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cencora Inc.
Exchange NYSE | Headquaters Conshohocken, PA, United States | ||
IPO Launch date 1995-04-04 | President, CEO & Director Dr. Robert P. Mauch Ph.D., PharmD | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 51000 | Website https://www.cencora.com |
Full time employees 51000 | Website https://www.cencora.com | ||
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.